Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Automated summary

Patients with cancer, especially those with hematologic malignancies, are considered among the very high-risk groups for priority COVID-19 vaccination due to the confluence of risk factors between cancer and the virus, which may increase exposure and suppress immune responses.